» Articles » PMID: 25268630

Dynamic Contrast Enhanced MRI Detects Early Response to Adoptive NK Cellular Immunotherapy Targeting the NG2 Proteoglycan in a Rat Model of Glioblastoma

Overview
Journal PLoS One
Date 2014 Oct 1
PMID 25268630
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

There are currently no established radiological parameters that predict response to immunotherapy. We hypothesised that multiparametric, longitudinal magnetic resonance imaging (MRI) of physiological parameters and pharmacokinetic models might detect early biological responses to immunotherapy for glioblastoma targeting NG2/CSPG4 with mAb9.2.27 combined with natural killer (NK) cells. Contrast enhanced conventional T1-weighted MRI at 7±1 and 17±2 days post-treatment failed to detect differences in tumour size between the treatment groups, whereas, follow-up scans at 3 months demonstrated diminished signal intensity and tumour volume in the surviving NK+mAb9.2.27 treated animals. Notably, interstitial volume fraction (ve), was significantly increased in the NK+mAb9.2.27 combination therapy group compared mAb9.2.27 and NK cell monotherapy groups (p = 0.002 and p = 0.017 respectively) in cohort 1 animals treated with 1 million NK cells. ve was reproducibly increased in the combination NK+mAb9.2.27 compared to NK cell monotherapy in cohort 2 treated with increased dose of 2 million NK cells (p<0.0001), indicating greater cell death induced by NK+mAb9.2.27 treatment. The interstitial volume fraction in the NK monotherapy group was significantly reduced compared to mAb9.2.27 monotherapy (p<0.0001) and untreated controls (p = 0.014) in the cohort 2 animals. NK cells in monotherapy were unable to kill the U87MG cells that highly expressed class I human leucocyte antigens, and diminished stress ligands for activating receptors. A significant association between apparent diffusion coefficient (ADC) of water and ve in combination NK+mAb9.2.27 and NK monotherapy treated tumours was evident, where increased ADC corresponded to reduced ve in both cases. Collectively, these data support histological measures at end-stage demonstrating diminished tumour cell proliferation and pronounced apoptosis in the NK+mAb9.2.27 treated tumours compared to the other groups. In conclusion, ve was the most reliable radiological parameter for detecting response to intralesional NK cellular therapy.

Citing Articles

Natural course of apparent diffusion coefficient (ADC) change after brain ischemic stroke: an alternative explanation by the triphasic relationship between T2 and ADC.

Wang Y Quant Imaging Med Surg. 2024; 14(12):9848-9855.

PMID: 39698594 PMC: 11651947. DOI: 10.21037/qims-24-2383.


The relevance of T2 relaxation time in interpreting MRI apparent diffusion coefficient (ADC) map for musculoskeletal structures.

Wang Y, Aparisi Gomez M, Ruiz Santiago F, Bazzocchi A Quant Imaging Med Surg. 2023; 13(12):7657-7666.

PMID: 38106333 PMC: 10722044. DOI: 10.21037/qims-23-1392.


Dynamic Contrast Enhanced Study in Multiparametric Examination of the Prostate-Can We Make Better Use of It?.

Guljas S, Bensic M, Krivdic Dupan Z, Pavlovic O, Krajina V, Pavokovic D Tomography. 2022; 8(3):1509-1521.

PMID: 35736872 PMC: 9231365. DOI: 10.3390/tomography8030124.


Establishing Imaging Biomarkers of Host Immune System Efficacy during Glioblastoma Therapy Response: Challenges, Obstacles and Future Perspectives.

Candiota A, Arus C Metabolites. 2022; 12(3).

PMID: 35323686 PMC: 8950145. DOI: 10.3390/metabo12030243.


The Extension of the LeiCNS-PK3.0 Model in Combination with the "Handshake" Approach to Understand Brain Tumor Pathophysiology.

Hirasawa M, Saleh M, de Lange E Pharm Res. 2022; 39(7):1343-1361.

PMID: 35258766 PMC: 9246813. DOI: 10.1007/s11095-021-03154-1.


References
1.
Smith F, Rauch C, Williams D, March C, Arthur D, Hilden J . The human homologue of rat NG2, a chondroitin sulfate proteoglycan, is not expressed on the cell surface of normal hematopoietic cells but is expressed by acute myeloid leukemia blasts from poor-prognosis patients with abnormalities of chromosome.... Blood. 1996; 87(3):1123-33. View

2.
Chekenya M, Hjelstuen M, Enger P, Thorsen F, Jacob A, Probst B . NG2 proteoglycan promotes angiogenesis-dependent tumor growth in CNS by sequestering angiostatin. FASEB J. 2002; 16(6):586-8. DOI: 10.1096/fj.01-0632fje. View

3.
Chinot O, Macdonald D, Abrey L, Zahlmann G, Kerloeguen Y, Cloughesy T . Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep. 2013; 13(5):347. PMC: 3631110. DOI: 10.1007/s11910-013-0347-2. View

4.
Chekenya M, Enger P, Thorsen F, Tysnes B, Al-Sarraj S, Read T . The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human malignant brain tumours. Neuropathol Appl Neurobiol. 2002; 28(5):367-80. DOI: 10.1046/j.1365-2990.2002.00412.x. View

5.
Yankeelov T, Lepage M, Chakravarthy A, Broome E, Niermann K, Kelley M . Integration of quantitative DCE-MRI and ADC mapping to monitor treatment response in human breast cancer: initial results. Magn Reson Imaging. 2007; 25(1):1-13. PMC: 2634832. DOI: 10.1016/j.mri.2006.09.006. View